Kura Oncology, Inc.
(NASDAQ : KURA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1304.25m
AMGNAmgen Inc.
0.97%203.881.2%$668.70m
GILDGilead Sciences, Inc.
0.77%69.180.9%$573.91m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$483.46m
BIIBBiogen Inc.
-0.27%337.421.3%$447.04m
ILMNIllumina, Inc.
0.87%312.753.5%$347.89m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$335.60m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$319.89m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$239.84m
TSROTESARO, Inc.
0.03%74.9614.4%$182.44m
AAgilent Technologies, Inc.
2.10%72.311.5%$161.80m
INCYIncyte Corporation
-0.32%78.422.5%$154.32m
EXASExact Sciences Corporation
4.19%78.8025.3%$153.44m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$139.57m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$126.24m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.